-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Chikungunya -X- _ O
virus -X- _ O
( -X- _ O
CHIKV -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
re-emerging -X- _ O
arbovirus -X- _ O
associated -X- _ O
with -X- _ O
febrile -X- _ O
illness -X- _ O
often -X- _ O
accompanied -X- _ O
by -X- _ O
rash -X- _ O
and -X- _ O
arthralgia -X- _ O
that -X- _ O
may -X- _ O
persist -X- _ O
for -X- _ O
several -X- _ O
years. -X- _ O
Outbreaks -X- _ O
are -X- _ O
associated -X- _ O
with -X- _ O
high -X- _ O
morbidity -X- _ O
and -X- _ O
create -X- _ O
a -X- _ O
public -X- _ O
health -X- _ O
challenge -X- _ O
for -X- _ O
countries -X- _ O
affected. -X- _ O
Recent -X- _ O
outbreaks -X- _ O
have -X- _ O
occurred -X- _ O
in -X- _ O
both -X- _ O
Europe -X- _ O
and -X- _ O
the -X- _ O
Americas -X- _ O
, -X- _ O
suggesting -X- _ O
CHIKV -X- _ O
may -X- _ O
continue -X- _ O
to -X- _ O
spread. -X- _ O
Despite -X- _ O
the -X- _ O
sustained -X- _ O
threat -X- _ O
of -X- _ O
the -X- _ O
virus -X- _ O
, -X- _ O
there -X- _ O
is -X- _ O
no -X- _ O
approved -X- _ O
vaccine -X- _ O
or -X- _ O
antiviral -X- _ O
therapy -X- _ O
against -X- _ O
CHIKV. -X- _ O
Therefore -X- _ O
, -X- _ O
it -X- _ O
is -X- _ O
critical -X- _ O
to -X- _ O
develop -X- _ O
a -X- _ O
vaccine -X- _ O
that -X- _ O
is -X- _ O
both -X- _ O
well -X- _ O
tolerated -X- _ O
and -X- _ O
highly -X- _ O
protective -X- _ O
. -X- _ O

METHODOLOGY -X- _ O
/ -X- _ O
PRINCIPAL -X- _ O
FINDINGS -X- _ O
: -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
describe -X- _ O
the -X- _ O
construction -X- _ O
and -X- _ O
characterization -X- _ O
of -X- _ O
a -X- _ O
modified -X- _ B-Intervention
Vaccinia -X- _ I-Intervention
virus -X- _ I-Intervention
Ankara -X- _ I-Intervention
( -X- _ I-Intervention
MVA -X- _ I-Intervention
) -X- _ I-Intervention
virus -X- _ I-Intervention
expressing -X- _ O
CHIKV -X- _ O
E3 -X- _ O
and -X- _ O
E2 -X- _ O
proteins -X- _ O
( -X- _ O
MVA-CHIK -X- _ O
) -X- _ O
that -X- _ O
protected -X- _ B-Outcome
several -X- _ I-Outcome
mouse -X- _ I-Outcome
models -X- _ I-Outcome
from -X- _ I-Outcome
challenge -X- _ I-Outcome
with -X- _ I-Outcome
CHIKV. -X- _ I-Outcome
In -X- _ O
particular -X- _ O
, -X- _ O
BALB -X- _ B-Patient
/ -X- _ I-Patient
c -X- _ I-Patient
mice -X- _ I-Patient
were -X- _ O
completely -X- _ B-Outcome
protected -X- _ I-Outcome
against -X- _ I-Outcome
viremia -X- _ I-Outcome
upon -X- _ I-Outcome
challenge -X- _ I-Outcome
with -X- _ I-Outcome
CHIKV -X- _ I-Outcome
after -X- _ I-Outcome
two -X- _ I-Outcome
doses -X- _ I-Outcome
of -X- _ I-Outcome
MVA-CHIK. -X- _ I-Outcome
Additionally -X- _ B-Outcome
, -X- _ I-Outcome
A129 -X- _ I-Outcome
mice -X- _ I-Outcome
( -X- _ I-Outcome
deficient -X- _ I-Outcome
in -X- _ I-Outcome
IFNα -X- _ I-Outcome
/ -X- _ I-Outcome
β -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
protected -X- _ I-Outcome
from -X- _ I-Outcome
viremia -X- _ I-Outcome
, -X- _ I-Outcome
footpad -X- _ I-Outcome
swelling -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
mortality. -X- _ I-Outcome
While -X- _ I-Outcome
high -X- _ I-Outcome
anti-virus -X- _ I-Outcome
antibodies -X- _ I-Outcome
were -X- _ I-Outcome
elicited -X- _ I-Outcome
, -X- _ I-Outcome
low -X- _ I-Outcome
or -X- _ I-Outcome
undetectable -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibodies -X- _ I-Outcome
were -X- _ I-Outcome
produced -X- _ I-Outcome
in -X- _ I-Outcome
both -X- _ I-Outcome
mouse -X- _ I-Outcome
models. -X- _ I-Outcome
However -X- _ I-Outcome
, -X- _ I-Outcome
passive -X- _ I-Outcome
transfer -X- _ I-Outcome
of -X- _ I-Outcome
MVA-CHIK -X- _ I-Outcome
immune -X- _ I-Outcome
serum -X- _ I-Outcome
to -X- _ I-Outcome
naïve -X- _ I-Outcome
mice -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
protect -X- _ I-Outcome
against -X- _ I-Outcome
mortality -X- _ I-Outcome
, -X- _ I-Outcome
suggesting -X- _ I-Outcome
that -X- _ I-Outcome
antibodies -X- _ I-Outcome
may -X- _ I-Outcome
not -X- _ I-Outcome
be -X- _ I-Outcome
the -X- _ I-Outcome
main -X- _ I-Outcome
effectors -X- _ I-Outcome
of -X- _ I-Outcome
protection -X- _ I-Outcome
afforded -X- _ I-Outcome
by -X- _ I-Outcome
MVA-CHIK.Furthermore -X- _ I-Outcome
, -X- _ I-Outcome
depletion -X- _ I-Outcome
of -X- _ I-Outcome
CD4 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
not -X- _ I-Outcome
CD8 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T-cells -X- _ I-Outcome
from -X- _ I-Outcome
vaccinated -X- _ I-Outcome
mice -X- _ I-Outcome
resulted -X- _ I-Outcome
in -X- _ I-Outcome
100 -X- _ I-Outcome
% -X- _ I-Outcome
mortality -X- _ I-Outcome
, -X- _ I-Outcome
implicating -X- _ I-Outcome
the -X- _ I-Outcome
indispensable -X- _ I-Outcome
role -X- _ I-Outcome
of -X- _ I-Outcome
CD4 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T-cells -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
protection -X- _ I-Outcome
afforded -X- _ I-Outcome
by -X- _ I-Outcome
MVA-CHIK. -X- _ I-Outcome
CONCLUSIONS -X- _ O
/ -X- _ O
SIGNIFICANCE -X- _ O
: -X- _ O
The -X- _ O
results -X- _ O
presented -X- _ O
herein -X- _ O
demonstrate -X- _ O
the -X- _ O
potential -X- _ O
of -X- _ O
MVA -X- _ O
to -X- _ O
effectively -X- _ O
express -X- _ O
CHIKV -X- _ O
E3-E2 -X- _ O
proteins -X- _ O
and -X- _ O
generate -X- _ O
protective -X- _ O
immune -X- _ O
responses. -X- _ O
Our -X- _ O
findings -X- _ O
challenge -X- _ O
the -X- _ O
assumption -X- _ O
that -X- _ O
only -X- _ O
neutralizing -X- _ O
antibodies -X- _ O
are -X- _ O
effective -X- _ O
in -X- _ O
providing -X- _ O
protection -X- _ O
against -X- _ O
CHIKV -X- _ O
, -X- _ O
and -X- _ O
provides -X- _ O
a -X- _ O
framework -X- _ O
for -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
novel -X- _ O
, -X- _ O
more -X- _ O
effective -X- _ O
vaccine -X- _ O
strategies -X- _ O
to -X- _ O
combat -X- _ O
CHIKV -X- _ O
. -X- _ O

